Company intelligence / Profile preview

Osivax

Lyon, Auvergne-Rhône-Alpes, Franceosivax.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Osivax has demonstrated promising results in clinical trials for its universal influenza vaccine candidate OVX836. Over Phase 1 and Phase 2a trials involving more than 1,200 subjects, the company reported a good safety profile, strong NP-specific cellular immune responses, and initial efficacy signals. A large international Phase 2b field efficacy study with over 2,800 participants is ongoing[1][3].

Therapeutic areas: Infectious Diseases
Modalities: Self-assembling nanoparticle vaccines (oligoDOM™ platform)T-cell vaccines combined with antibody-based approaches
Industry: Biotech

Drug pipeline

4 assets

OVX313

Approved

3 more assets in the full pipeline.

Request access →

Partnerships

Meiji Seika Pharma Co., Ltd. (strategic investor and partner for infectious disease expertise)[3]

Beyond the preview

Go deeper on Osivax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Osivax.

Explore the full profile